Market research
MLND Millendo Therapeutics, Inc
NASDAQ USD Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 20M
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- 0.0%
- Beta
- 0.48
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 20M
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- 0.0%
- Beta
- 0.48
About
About Millendo Therapeutics, Inc
As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.
Research context
Millendo Therapeutics, Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the MLND discussion.
5 years, 7 months ago
Millendo Therapeutics, Inc is currently in a long term downtrend where the price is trading 43.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Millendo Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 100.3% to $36K since the same quarter in the previous year.
Finally, its free cash flow grew by 314.4% to $25M since the same quarter in the previous year.
Based on the above factors, Millendo Therapeutics, Inc gets an overall score of 3/5.